[Assessment of efficacy and safety of nebivolol in patients with stable effort angina].
OBJECTIVE
To study efficacy and safety of nebivolol in patients with stable angina pectoris.


METHODS
Twenty patients with stable effort angina pectoris and positive exercise test without contraindications to beta-blockers, signs of NYHA class III-IV heart failure, and obstructive lung disease. After 5-7 days of control period all patients were given nebivolol (starting dose 5 mg/day) for 8 weeks. Graded exercise tests on treadmill and patient's diaries were used for assessment of treatment efficacy.


RESULTS
Treatment with nebivolol (5-10 mg o.d. ) was associated with significant slowing of heart rate, lowering of blood pressure, and increase of exercise duration until appearance of angina or 1 mm ST-segment depression. Nebivolol did not affect left ventricular ejection fraction, bronchial conductance, or results of biochemical tests (including lipid profile). Adverse reaction (dizziness which disappeared after lowering of a dose) was registered in 1 patient.


CONCLUSIONS
Nebivolol is an effective drug for the treatment of patients with stable angina.
Makolkin
V I
VI
Sulimov
V A
VA
Gavrilov
Yu V
YV
Petriĭ
V V
VV
Aksel'rod
A S
AS
Buval'tsev
V I
VI
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D001578:Benzopyrans / Q000627:therapeutic use*; D004983:Ethanolamines / Q000627:therapeutic use*; D005080:Exercise Test; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol; D005082:Physical Exertion; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol